Prognose

Kaufen	1
Halten	0
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda ® when administered via Interventional Radiology (IR) in patients with deep- seated tumors without associated cutaneous tumors TAMPA, Fla. , May 5, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the initiation of its Phase 1b/2a trial of IFx-Hu2.0, TuHURA's lead innate immune agonist, in patients with MCCUP who would not be eligible for the Company's planned Phase 3 accelerated approval trial, which is targeted to begin enrollment later in Q2 2025.» Mehr auf prnewswire.com
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
Kineta presents updated clinical data from VISTA-101 trial of KVA12123, demonstrating >90% VISTA receptor occupancy at 1,000mg dose level throughout the trial's every two weekly dosing interval (Q2W) TuHURA's Phase 3-ready IFx2.0 produced clinically meaningful anti-tumor responses and abscopal effect, after checkpoint inhibitor (CPI) therapy failure in patients with advanced melanoma when rechallenged with CPI TAMPA, Fla., April 28, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today reported on poster presentations of Kineta Inc.'s ("Kineta") KVA12123 novel anti-VISTA antibody and TuHURA's IFx-Hu2.0 in advanced melanoma and at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.» Mehr auf prnewswire.com
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
TAMPA, Fla. , April 8, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that an abstract highlighting Kineta Inc.'s novel KVA12123 antibody and an abstract from Moffitt Cancer Center scientists examining the mechanisms of Company's IFx-Hu2.0 therapy in advanced melanoma have been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte TuHURA Biosciences einen Umsatz von 0,00€ und ein Nettoeinkommen von −5,76 Mio€

(EUR)	Dez. 2024	YOY
Umsatz	0,00	-
Bruttoeinkommen	−16,95k	24,90%
Nettoeinkommen	−5,76 Mio	522,65%
EBITDA	−5,24 Mio	474,95%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+156,42 Mio€
Anzahl Aktien	43,68 Mio
52 Wochen-Hoch/Tief	+12,97€ - +1,60€
Dividenden	Nein
Beta	0,52
KGV (PE Ratio)	−15,73
KGWV (PEG Ratio)	−0,16
KBV (PB Ratio)	+11,69
KUV (PS Ratio)	0,00

Unternehmensprofil

TuHURA Biosciences, Inc. ist ein immunonkologisches Unternehmen in der Phase 3 der Zulassungsphase und entwickelt neuartige Technologien zur Überwindung von Resistenzen gegen Krebsimmuntherapien. Der Hauptsitz des Unternehmens befindet sich in Tampa, FL.